Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
ADELA, an international phase III study being conducted across multiple countries, combines…
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
ADELA, an international phase III study being conducted across multiple countries, combines…
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
ADELA, an international phase III study being conducted across multiple countries, combines…
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
ADELA, an international phase III study being conducted across multiple countries, combines…
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE…
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival…
Brain Cancer Canada Awards a $50,000 Grant to Discover How to Use the Bodys Own Immune Cells to Attack Pediatric Brain Cancers
December 10, 2024 10:00 ET | Source: Brain Cancer Canada TORONTO, Dec.…
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in…
Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
December 05, 2024 08:00 ET | Source: Theriva Biologics, Inc. ROCKVILLE, Md.,…
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
December 03, 2024 16:05 ET | Source: Beyond Air™ The Phase 1b…